Ketamine and Spravato are noninferior to ECT in a 2023 head-to-head trial with fewer memory side effects; TMS avoids memory risk entirely; MAOIs and psilocybin trials are further options for treatment-resistant depression.
If you are dealing with severe depression, real alternatives to electroconvulsive therapy (ECT) exist. You do not have to accept an induced seizure or general anesthesia to find relief from severe or treatment-resistant depression (TRD). Depending on your medical history, your insurance coverage, and how quickly you need relief, your primary options include transcranial magnetic stimulation (TMS), sub-anesthetic ketamine, Food and Drug Administration (FDA) approved esketamine nasal spray, and older antidepressant classes like monoamine oxidase inhibitors (MAOIs). Emerging options like psilocybin are also becoming available in regulated state programs.
At Mind Medicine Law, we track clinical research and legal frameworks to help you evaluate which treatments match your specific needs. Understanding your options gives you leverage when discussing next steps with your psychiatrist. This guide covers five evidence-backed alternatives to ECT, detailing their mechanisms, practical costs, and trade-offs so you can decide what to pursue next.
Electroconvulsive therapy (ECT) works by inducing a brief, controlled brain seizure using electrical stimulation. The procedure takes place under general anesthesia with an intravenous muscle relaxant so your body does not physically convulse during the seizure. A psychiatrist and an anesthesia team manage each session in a hospital or specialized outpatient surgical suite with continuous cardiac and respiratory monitoring. A standard ECT course usually requires 6 to 12 sessions delivered over 2 to 4 weeks, with 2 to 3 visits each week. Many patients also receive ongoing maintenance sessions to prevent relapse. ECT has the longest and deepest evidence base of any depression treatment in psychiatry, and major clinical reviews still rate it as the most effective intervention for the most severe forms of depression.
Even with high response rates, many people look for alternatives because of the memory-related side effects. ECT commonly causes short-term memory loss around the time of treatment, making it difficult to retain new information during the treatment weeks. Less commonly, patients experience gaps in memory for events that occurred before the treatment, a condition doctors call retrograde amnesia, meaning losing memories of events that happened before the treatment. A 2007 long-term follow-up study led by Sackeim and colleagues6, along with a 2003 systematic review by the UK ECT Review Group in The Lancet7, showed that while memory difficulties are temporary for some people, they can be persistent for others. How much memory disruption you experience depends on your individual biology, the electrical dose, and whether electrodes are placed on one side of your head or both.
The practical burden of ECT also prompts patients to seek other options. Each visit requires general anesthesia, which means fasting beforehand, having an intravenous line placed, and taking several hours to recover from grogginess. You cannot drive yourself home from the hospital, so you need a family member or caregiver to accompany you to every single appointment. Although Medicare and commercial health insurance widely cover ECT for severe and treatment-resistant depression, attending hospital sessions multiple times a week disrupts jobs, school, and childcare. Many people reach this crossroad simply because standard daily antidepressants failed. Data from the STAR*D trial published by Rush and colleagues in 20068 showed that roughly half of people who try a selective serotonin reuptake inhibitor (SSRI) do not achieve full remission on their first medication. Failing standard oral medications does not mean you have to jump straight to a hospital surgical suite.
If you need rapid symptom relief without anesthesia or an induced seizure, ketamine is the fastest pharmacological alternative available. Ketamine works as an N-methyl-D-aspartate (NMDA) glutamate receptor antagonist. Instead of slowly altering serotonin levels, it acts on glutamate, the brain’s primary excitatory neurotransmitter. At sub-anesthetic doses, ketamine produces noticeable antidepressant effects, often within hours to a few days after your first dose. You do not need to go to an operating room, and you do not lose consciousness during the treatment.
Clinical research shows that ketamine can match the effectiveness of ECT for many patients. A 2023 trial published in the New England Journal of Medicine (NEJM) by Anand and colleagues1 directly compared intravenous ketamine to ECT in patients with nonpsychotic treatment-resistant depression. The researchers found that ketamine was noninferior to ECT, meaning it worked at least as well, with a lower rate of memory-related side effects among the people who got ketamine. Ketamine’s primary cognitive side effect is dissociation, which causes a temporary feeling of detachment from your physical body or your surroundings during the session. This sensation resolves completely within an hour or two as your body metabolizes the medicine. Long-term memory loss is not an established concern at the doses used for depression. Read our full ketamine vs ECT comparison for the complete side-by-side breakdown.
You can access ketamine through several different medical and legal channels:
Transcranial magnetic stimulation (TMS) provides a non-invasive, device-based alternative to ECT that avoids medications and anesthesia entirely. TMS is an FDA-cleared medical device that delivers focused magnetic pulses through an electromagnetic coil placed gently against your scalp. These magnetic pulses stimulate nerve cells in your prefrontal cortex, the brain region responsible for mood regulation. Unlike ECT, TMS does not cause a brain seizure. You remain fully awake, sitting upright in an office chair, and you can chat with the technician or listen to music throughout the session.
Because TMS uses magnetic fields rather than electrical currents or systemic drugs, it has a very clean side-effect profile. You will not experience the physical side effects common to oral medications, such as weight gain, sexual dysfunction, digestive issues, or daytime sleepiness. Most importantly, TMS does not carry ECT’s memory-related risks. You have no cognitive downtime, no memory gaps, and no post-anesthesia confusion. You can drive yourself to your appointment, complete your session, and return directly to work or family responsibilities.
A standard TMS treatment course requires 20 to 36 sessions scheduled over 4 to 6 weeks, typically running five days a week for 20 to 40 minutes per visit. Most commercial insurance plans and Medicare cover TMS after you have failed two antidepressant medications, which is the exact same coverage requirement applied to Spravato. For patients who cannot spend six weeks in treatment, researchers developed accelerated TMS, also known as the SAINT protocol. Developed at Stanford University and published by Cole and colleagues in the American Journal of Psychiatry in 20203, this accelerated protocol delivers 10 short sessions in a single day across several consecutive days. In small clinical trials, accelerated TMS achieved remission and response rates above 80 percent. While accelerated TMS is not yet widely accessible in community clinics, it shows how non-invasive magnetic treatments are shortening the time needed to achieve clinical relief. Compare TMS and ketamine directly in our ketamine vs TMS guide, or see our existing TMS alternatives roundup if TMS itself is not working for you.
Psilocybin represents a novel, psychedelic alternative currently moving through advanced clinical development and state-level access frameworks. Psilocybin is a serotonin 5-HT2A receptor agonist found in certain species of mushrooms. In therapeutic settings, it produces temporary shifts in perception, introspection, and emotional processing that can help disrupt chronic depressive thinking. Unlike daily pills, psilocybin is administered in one or two discrete, supervised sessions supported by preparation and follow-up counseling.
At the federal level, psilocybin remains classified as a Schedule I controlled substance and does not yet have FDA marketing approval. However, pharmaceutical development has reached late stages. In 2025, COMPASS Pathways announced positive Phase 3 clinical trial results4 for its COMP360 synthetic psilocybin formulation in patients with treatment-resistant depression. This development indicates that prescription psilocybin may eventually enter medical practice as a regulated treatment option alongside devices and nasal sprays.
If you want to pursue psilocybin today, you can access it legally through state-regulated programs without waiting for federal rescheduling. Oregon voters passed Measure 109 and Colorado voters passed Proposition 122, establishing state frameworks where adults age 21 and older can receive psilocybin at licensed service centers. You do not need a medical diagnosis, a doctor’s prescription, or an insurance referral to book an appointment. A standard session lasts between 4 and 8 hours under the continuous monitoring of a trained session guide. The primary hurdles are cost and travel: health insurance does not cover state-level psilocybin services, and a single session generally costs between $1,000 and $3,500. See our full psilocybin guide for legal status by state and access details.
Before committing to procedural interventions like ECT, reviewing your medication history can uncover effective oral options that doctors frequently overlook. When people fail to recover after trying two different SSRIs or serotonin-norepinephrine reuptake inhibitors (SNRIs), they are often told they have exhausted medication options. In reality, modern psychiatry often overlooks older drug classes that operate through broader neurochemical mechanisms. The STAR*D study established that roughly 50 percent of patients do not achieve remission on their first antidepressant trial, yet many clinicians move toward device therapies or hospital procedures without testing every medication class.
Monoamine oxidase inhibitors (MAOIs) are among the most effective oral antidepressants ever developed. This class includes medications such as phenelzine (Nardil), tranylcypromine (Parnate), and isocarboxazid (Marplan). Multiple meta-analyses, including a comprehensive 2006 analysis by Henkel and colleagues in Psychiatry Research5, demonstrated that MAOIs outperform newer antidepressants in treating atypical depression and severe, treatment-resistant symptoms. MAOIs prevent the breakdown of serotonin, dopamine, and norepinephrine simultaneously, providing broad neurotransmitter support.
Physicians underuse MAOIs today because the medications require strict dietary and prescription precautions. While taking an MAOI, you must avoid foods rich in tyramine, including aged cheeses, cured meats, draft beers, red wine, soy sauce, and fermented foods. Consuming high-tyramine items can trigger a sudden, dangerous spike in blood pressure, known as a hypertensive crisis. You also cannot combine MAOIs with most standard antidepressants, stimulants, or certain pain medications, requiring a multi-week washout period before switching. For patients facing the prospect of general anesthesia, memory loss, and frequent hospital visits from ECT, adhering to a dietary food list is often a far more acceptable compromise. Compare medication routes directly in our ketamine vs antidepressants guide or our SSRI alternatives roundup.
| Alternative | How it works | Typical course | Cost / coverage | Key limitation |
|---|---|---|---|---|
| Ketamine / Spravato | NMDA glutamate receptor antagonist. No anesthesia or seizure. | Often relief within hours to days; Spravato twice weekly, tapering. | Spravato often covered; IV/IM $400–800/session; telehealth $150–400/month | Dissociation during dosing; newer evidence base than ECT |
| TMS (incl. accelerated/SAINT) | Magnetic pulses to the prefrontal cortex. No anesthesia, no seizure. | 20–36 sessions over 4–6 weeks; SAINT: 10 sessions in 1 day | Often covered after 2 failed antidepressants | Multi-week time commitment (standard protocol); SAINT not widely available |
| Psilocybin therapy | 5-HT2A serotonin receptor agonist, guided session | 1–2 sessions, 4–8 hours each, with prep and integration | No insurance coverage; $1,000–3,500 out of pocket | Legal access only in Oregon and Colorado; Schedule I federally |
| MAOIs | Blocks breakdown of serotonin, dopamine, and norepinephrine | Daily oral medication | Generic, usually covered | Strict tyramine diet; interacts with most other psychiatric drugs |
| ECT (for comparison) | Induced seizure under general anesthesia | 6–12 sessions over 2–4 weeks, plus possible maintenance | Widely covered by insurance and Medicare | Memory-related side effects; anesthesia and hospital logistics |
Although alternatives like ketamine, TMS, and MAOIs offer substantial advantages in convenience and cognitive safety, they are not appropriate for every clinical scenario. ECT has been practiced and refined for over eight decades, giving it an extensive clinical track record that no newer treatment can fully match. In specific life-threatening psychiatric emergencies, major psychiatric guidelines continue to recommend ECT as the primary, first-line standard of care.
You should not rely on outpatient alternatives if you or a family member is dealing with any of the following acute conditions:
If you are facing one of these urgent conditions, you should speak directly with your psychiatrist or visit an emergency psychiatric facility rather than attempting to schedule outpatient alternatives. Trying to secure private ketamine appointments, commit to a six-week daily TMS schedule, or plan travel to an Oregon psilocybin center introduces delays that can put your physical safety at risk. In those situations, ECT remains the safest and most reliable intervention available.
Our comparison of ECT alternatives reflects current clinical trial data, medical device availability, and legal regulations in 2026. This assessment could shift as researchers complete larger clinical studies and regulatory agencies adjust drug classifications. Several specific developments would directly alter which treatments represent the strongest alternatives to ECT.
First, new head-to-head clinical trials evaluating long-term durability could make an alternative the better default over ECT. The 2023 NEJM trial by Anand and colleagues found that ketamine was not worse than ECT (noninferior) for nonpsychotic depression during acute treatment: 55.4 percent of the ketamine group responded to treatment after three weeks, compared with 41.2 percent of the ECT group. However, if larger trials show that ketamine or accelerated SAINT TMS maintains remission over six to twelve months with equal or better durability than ECT maintenance, ECT would lose its status as the default option for severe nonpsychotic cases. Second, broader insurance reimbursement would transform access. If commercial health plans and Medicare create routine billing coverage for off-label IV ketamine infusions and accelerated TMS protocols, out-of-pocket financial hurdles would disappear. Finally, if the FDA grants formal market approval for COMP360 psilocybin following its positive 2025 Phase 3 results, regulated psychedelic medicine would shift from state wellness facilities into mainstream medical coverage.
Until those regulatory and clinical changes occur, your treatment decision comes down to balancing symptom severity, speed, cognitive risks, and practical out-of-pocket costs. If you have moderate to severe nonpsychotic depression, exploring TMS, Spravato, or MAOIs offers a strong probability of relief without the memory complications of general anesthesia. To compare your clinical history against available ECT alternatives, use our depression treatment path tool to find the right path forward.
In terms of cognitive side effects, anesthesia risks, and daily disruption, TMS carries a lower risk profile than ECT. Transcranial magnetic stimulation (TMS) is an FDA-cleared outpatient procedure that uses magnetic pulses to stimulate prefrontal brain cells while you remain fully awake in an office chair. TMS causes no memory loss, requires no general anesthesia, and produces no systemic side effects like weight gain or sedation. In contrast, electroconvulsive therapy (ECT) requires general anesthesia, muscle relaxants, and an induced brain seizure, which carries documented risks of short-term memory disruption and gaps in past memory. However, for immediate medical emergencies like catatonia or severe psychotic depression, ECT has a much deeper evidence base and remains clinically necessary.
If a standard course of 6 to 12 ECT sessions does not relieve your depression, you still have medical alternatives to explore. First, your psychiatrist may evaluate whether changing electrical parameters, adjusting electrode placement, or trying maintenance ECT is appropriate. If you step away from ECT entirely, sub-anesthetic ketamine or FDA-approved Spravato (esketamine nasal spray) targets NMDA glutamate receptors, offering a biological pathway completely distinct from ECT. Another viable medical step is an older oral antidepressant class like monoamine oxidase inhibitors (MAOIs), including tranylcypromine and phenelzine, which have strong clinical trial data in treatment-resistant cases. You can also look into licensed psilocybin service centers in Oregon or Colorado, though any transition requires direct coordination with your doctor.
Modern alternatives to ECT include advanced neuromodulation devices, rapid-acting glutamate medications, and legal psychedelic therapies. Transcranial magnetic stimulation (TMS), including accelerated protocols like Stanford's SAINT protocol, stimulates brain tissue using magnetic fields without anesthesia or memory loss. Ketamine infusions and FDA-approved Spravato nasal spray target glutamate receptors to reduce depressive symptoms within hours to days. In addition, state-regulated psilocybin programs in Oregon and Colorado offer supervised psychedelic sessions under state law, supported by positive 2025 Phase 3 trial results from COMPASS Pathways for synthetic psilocybin.
You may not be a suitable candidate for ECT if you have severe cardiopulmonary conditions that make general anesthesia medically unsafe. Individuals whose careers or daily lives cannot accommodate temporary short-term memory disruption or the possibility of memory gaps are also poor candidates. Additionally, if you have nonpsychotic treatment-resistant depression and have not yet tried less invasive outpatient options like TMS, Spravato, or an MAOI, rushing into ECT is generally unnecessary. Finally, patients with active substance use disorders or medical conditions that your anesthesia team determines present excessive surgical risks should explore non-surgical alternatives first.
Whether ECT causes lasting damage is not settled the same way for every patient. A 2007 clinical evaluation led by Sackeim and colleagues found that while many people recover their short-term memory in the weeks after a treatment series, a subset of patients experience persistent gaps in memory for events that happened before the treatment. The severity and duration of memory disruption vary depending on whether electrodes are placed unilaterally or bilaterally, the electrical dosage used, and individual patient biology. If you are concerned about persistent memory changes, raise electrode placement technique and alternative options like TMS or ketamine with your psychiatrist before consenting to treatment.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.